ten23 health was founded in 2021 and is a contract development, manufacturing, and testing (“CDMO”) company for the biopharmaceutical industry, serving large pharma and innovative biotech clients.

Visit ten23.health

Overview

As drug development activities across biologics modalities continue to accelerate, small biotechs and large pharma companies will increasingly outsource key services requiring unique and market-tested expertise. 

Recognising this, we decided to create a contract development, manufacturing and testing (“CDMO”) company focused on delivering scientific expertise to both innovative biotechs and large bioparhama companies.

Headquartered in Basel, Switzerland, ten23 health’s core service offering includes drug product formulation and process development, aseptic fill & finish manufacturing, and GMP testing services for sterile pharmaceutical products. These high-value services are critical to helping pharma and biotech customers turn a molecule of interest into a viable sterile medicine that is optimised for manufacturability, patient access and ease of administration, and logistical favourability.

ten23 health will deliver services in an engrained, fair and sustainable manner, respecting the future of the planet and people’s health. 

How we add value 

We partnered with a highly-experienced team of experts, including Prof. Dr Hanns Christian Mahler, with a proven track record in pharmaceutical product design and development to launch ten23 health in 2021.

Since then, we have supported the company’s acquisition of Swissfillon, an innovative sterile fill & finish CDMO focused on complex biologics and innovative containers and devices, creating a vertically integrated CDMO with ten23’s Basel development lab and Swissfillon’s differentiated fill & finish manufacturing.

Regulatory information
This transaction involved a recommendation of 3i Investments plc.